Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Терапевтический архив

Vera A. Zherebtsova¹  Kamil D. Kaplanov¹  Vladimir I. Vorobyev¹  Lev S. Butaev¹  Vadim V. Ptushkin¹  Ridvan K. Ilyasov²  Elena V. Martynova³  Eduard G. Gemdzhian⁴  Oleg V. Margolin⁴  Ekaterina S. Nesterova⁴  Elena V. Melnichenko⁵  Liudmila V. Fedorova⁶  Natalia B. Mikhailova⁶  Elena P. Chumakova⁷  Elena V. Tarasenko⁸  Natalia B. Bulieva⁹  Elena P. Yakovleva^1,10  Liliia P. Kaleikina^1,11  Olga Yu. Li^1,12  Olga S. Trubyakova^1,13 

[1] Botkin City Clinical Hospital;Efetov Crimean Republican Oncological Clinical Dispensary;Krasnoyarsk Regional Clinical Hospital;National Research Center for Hematology;Novosibirsk Hematology Center;Pavlov First Saint Petersburg State Medical University;Perm Regional Clinical Hospital;Pirogov City hospital №1;Regional Clinical Hospital of the Kaliningrad Region;Regional Clinical Hospital;Republican Oncological Dispensary;Sakhalin Regional Clinical Hospital;Vladimir City Clinical Hospital №5;

关键词: ibrutinib;    mantle cell lymphoma;    real-world practice;    refractory;    relapsed;   

DOI  :  10.26442/00403660.2021.07.200930

来源: DOAJ

【 授权许可】

Unknown